SCHEMBL6694348

SCHEMBL6694348

COC(=O)COc1ccc(Cl)c2[nH]c3cccc(C(N)=O)c3c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
MAPT P10636 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
JAK2 O60674 2/20 0.38
PLA2G2A P14555 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
PARP1 P09874 2/20 0.36
TP53 P04637 2/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
PBRM1 Q86U86 1/20 0.35
CLCN2 P51788 1/20 0.35
PTGDR Q13258 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6693792 0.75 PBRM1 (0.43) LMNAMAPTJAK2PARP1TSHR
SCHEMBL6695147 0.74 PLA2G2A (0.58) PLA2G2A
SCHEMBL6693606 0.72 PARP1 (0.46) LMNAMAPTJAK2PLA2G2APARP1
SCHEMBL30007166 0.71 PLA2G2A (0.46) MAPTPLA2G2ASMN1; SMN2PARP1HTT
SCHEMBL25044302 0.70 PARP1 (0.58) LMNAMAPTNPC1RAB9ACASP3
SCHEMBL4573655 0.68 PTGDR (0.55) LMNAMAPTNPC1RAB9AGAA
SCHEMBL6691907 0.68 PLA2G2A (0.60) PLA2G2A
SCHEMBL30007625 0.68 PLA2G2A (0.35) RAB9APLA2G2ASMN1; SMN2PARP1HTT
SCHEMBL6697348 0.67 PLA2G2A (0.57) PLA2G2A
SCHEMBL29966742 0.67 MEN1 (0.45) MAPTJAK2PARP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0950657-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors LILLY CO ELI (US) 2004-07-14 EP disclosed
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed
EP-0950657-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors ELI LILLY AND COMPANY (US) 1999-10-20 EP disclosed